Molgramostim

Phase 3

Savara Inc (SVRA)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Jun '27

SVRAPhase 3$1.0B

Molgramostim Phase 3 Est. Readout

Molgramostim• Autoimmune Pulmonary Alveolar Proteinosis5

Jun 2027~Estimated

CT.gov

00%

SVRAPDUFA$1.0B

Phase 3

FDA PDUFA Date Molgramostim (MOLBREEVI)

Molgramostim• Autoimmune pulmonary alveolar proteinosis

Nov 22Confirmed

Source

00%

Competitive Landscape

0 competitors in Autoimmune Pulmonary Alveolar Proteinosis

View Full Landscape

Drug Information

Target Indication

Autoimmune Pulmonary Alveolar Proteinosis

Clinical Trial

NCT04544293

Last updated: 2/13/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

SVRA

Savara Inc

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

Vancomycin inhalation powderPhase 3

MRSA

Molgramostim Open-labelPhase 3

Autoimmune Pulmonary Alveolar Proteinosis

Inhaled molgramostimPhase 2

Mycobacterium Infections, Nontuberculous

Vancomycin hydrochloride inhalation powderPhase 2

Cystic Fibrosis

Antimycobacterial regimenPhase 2

Mycobacterium Infections, Nontuberculous

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts